Ackerman Deborah L, Greenland Sander
Department of Epidemiology, School of Public Health, University of California, Los Angeles 90095-1772, USA.
J Clin Psychopharmacol. 2002 Jun;22(3):309-17. doi: 10.1097/00004714-200206000-00012.
Meta-analytic reviews of placebo-controlled studies for obsessive-compulsive disorder have found that clomipramine is more effective than drugs with more selective actions on serotonin reuptake, whereas in most direct comparisons, clomipramine's superiority has been less obvious. The authors used metaregression to identify sources of he-terogeneity in placebo-controlled trials of clomipramine, fluvoxamine, sertraline, and paroxetine. They evaluated such patient characteristics as age, gender, age of obsessive-compulsive disorder (OCD) onset, and baseline severity of OCD and depression, and such study characteristics as exclusion or inclusion criteria, length of single-blind prerandomization period, length of trial, number of subjects, and publication year. We found considerable heterogeneity across studies that was associated, in part, with publication year, length of single-blind prerandomization period, length of trial, and severity of patients' OCD. The apparent superiority of clomipramine persisted after controlling for these factors. The authors also confirmed previous reports that placebo response is higher in more recent studies. Meta-analyses can help characterize responders and nonresponders. The authors urge investigators to provide summaries of patient characteristics, especially baseline severity, age at onset, and duration of OCD, by patients' response.
对强迫症安慰剂对照研究的荟萃分析综述发现,氯米帕明比作用于5-羟色胺再摄取更具选择性的药物更有效,然而在大多数直接比较中,氯米帕明的优越性并不那么明显。作者采用元回归分析来确定氯米帕明、氟伏沙明、舍曲林和帕罗西汀安慰剂对照试验中的异质性来源。他们评估了患者特征,如年龄、性别、强迫症发病年龄以及强迫症和抑郁症的基线严重程度,以及研究特征,如排除或纳入标准、单盲随机化前期的时长、试验时长、受试者数量和发表年份。我们发现各研究之间存在相当大的异质性,部分与发表年份、单盲随机化前期的时长、试验时长以及患者强迫症的严重程度有关。在控制这些因素后,氯米帕明明显的优越性依然存在。作者还证实了先前的报道,即最近的研究中安慰剂反应更高。荟萃分析有助于对有反应者和无反应者进行特征描述。作者敦促研究人员按患者的反应提供患者特征摘要,尤其是基线严重程度、发病年龄和强迫症病程。